BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Reduces Holdings in Thermo Fisher Scientific Inc. $TMO

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 170,429 shares of the medical research company’s stock after selling 32,972 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Thermo Fisher Scientific were worth $84,805,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Cypress Advisory Group LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $253,000. Mondrian Investment Partners LTD boosted its holdings in shares of Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock valued at $106,738,000 after buying an additional 127,357 shares in the last quarter. GAMMA Investing LLC boosted its stake in Thermo Fisher Scientific by 22.0% during the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock worth $2,419,000 after acquiring an additional 877 shares in the last quarter. Deutsche Bank AG boosted its stake in Thermo Fisher Scientific by 9.5% during the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company’s stock worth $687,553,000 after acquiring an additional 114,277 shares in the last quarter. Finally, Hancock Whitney Corp boosted its stake in Thermo Fisher Scientific by 0.6% during the fourth quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company’s stock worth $2,802,000 after acquiring an additional 30 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Price Performance

TMO opened at $500.2380 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock has a market capitalization of $188.89 billion, a P/E ratio of 28.93, a P/E/G ratio of 2.58 and a beta of 0.74. The company’s 50-day simple moving average is $443.02 and its two-hundred day simple moving average is $457.46. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $52,037,916.68. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,896 shares of company stock worth $8,593,838 over the last three months. Insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of a number of analyst reports. Scotiabank raised Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. HSBC reissued a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Argus dropped their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Finally, UBS Group upped their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research note on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.